Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of yttrium-90 anti-CD66 radioimmunotherapy plus high-dose melphalan versus melphalan alone before autologous stem cell transplantation in multiple myeloma
2006-003424-12Phase 2Terminated
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jan 2007
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in multiple myeloma (MM) comparing Yttrium-90 anti-CD66 plus melphalan with Melphalan alone (2 arms). Primary endpoints: Complete remission rate after transplantation, Remission status pre and post transplantation and 1 more. Started Jan 2007; status: terminated.
02
Drugs
90Y-besilesomabmelphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2006-003424-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003424-12.